Physician profile
Nadeem Ansari
NPI 1073651808
$2,945.05
in general payments reported to CMS, 2019-2025
31 companies · $885 in 2025
The $885 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2021: $122 · 2022: $137 · 2023: $551 · 2024: $1,086 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.22 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $464.82 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.87 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $267.97 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $203.88 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.71 | 2022-2024 | Trulance, Xifaxan |
| Abbvie INC. | $187.74 | 2023-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $171.27 | 2024-2025 | |
| Pfizer INC. | $151.49 | 2019-2025 | |
| Abbott Laboratories | $117.96 | 2022-2025 | Freestyle Libre 3, Mitraclip, Proclaim |
| Dexcom, INC. | $114.76 | 2023-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $82.11 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $79.86 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $71.84 | 2023-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $64.48 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $55.53 | 2023-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $47.85 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $47.38 | 2023-2024 | Inspire |
| Jazz Pharmaceuticals INC. | $39.72 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $39.03 | 2023-2024 | Eliquis, Camzyos |
| Madrigal Pharmaceuticals | $34.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $31.74 | 2024-2025 | |
| Astellas Pharma US INC | $31.50 | 2019-2024 | Veozah |
| Iovance Biotherapeutics, INC. | $24.10 | 2025 | Amtagvi |
| Phadia US INC. | $20.34 | 2025 | Immunocap |
| Aimmune Therapeutics, INC. | $19.96 | 2025 | Vowst |
| Xeris Pharmaceuticals, INC. | $19.85 | 2025 | Gvoke Hypopen |
| Kyowa Kirin, INC. | $19.51 | 2024 | Crysvita |
| Acadia Pharmaceuticals INC | $17.91 | 2025 | Nuplazid |
| Glaxosmithkline, LLC. | $17.64 | 2025 | Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $16.61 | 2022 | |
| Resmed Corp | $14.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.